Showing results (121-130 of 173) with videos related to

Sort By:
Pageof 18
Respiratory Medicine|August 27, 2022
Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 studyKenneth R Chapman, Giorgio Walter Canonica, Kim L Lavoie, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 26, 2018
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME studyClaus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 24, 2021
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREOIan D Pavord, Kenneth R Chapman, Mona Bafadhel, et al.
Respiratory Medicine|May 25, 2016
Assessing biomarkers in a real-world severe asthma study (ARIETTA)Roland Buhl, Stephanie Korn, Andrew Menzies-Gow, et al.
The Lancet. Respiratory Medicine|July 13, 2020
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 studyHuib A M Kerstjens, Jorge Maspero, Kenneth R Chapman, et al.
American Journal of Respiratory and Critical Care Medicine|May 22, 2018
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical TrialKenneth R Chapman, John R Hurst, Stefan-Marian Frent, et al.
The European Respiratory Journal|August 31, 2019
Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPDJan Stolk, Naveh Tov, Kenneth R Chapman, et al.
Environmental Health Perspectives|May 30, 2009
A cohort study of traffic-related air pollution and mortality in Toronto, Ontario, CanadaMichael Jerrett, Murray M Finkelstein, Jeffrey R Brook, et al.
Respiratory Medicine|March 11, 2023
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM studyRichard N Van Zyl-Smit, Huib Am Kerstjens, Jorge F Maspero, et al.
Lancet (London, England)|June 1, 2015
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialKenneth R Chapman, Jonathan G W Burdon, Eeva Piitulainen, et al.
Pageof 18